Form 4: Kalaris Therapeutics Director Michael Dybbs Acquires 18,000 Stock Options

Director Michael Dybbs of Kalaris Therapeutics acquired 18,000 stock options on April 10, 2025, exercisable at $7.31, vesting over three years.

Summary

• On April 10, 2025, Michael Dybbs, a director of Kalaris Therapeutics, acquired 18,000 stock options.
• The exercise price of these options is $7.31.
• The options vest in equal monthly installments over three years, starting from March 18, 2025, and continuing through March 18, 2028, contingent upon continuous service.
• The options expire on April 9, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of three years with monthly installments is a typical arrangement to ensure continued service and commitment.
• The exercise price is usually set at or above the market price at the time of the grant.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised in the future.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates

Keywords

Kalaris Therapeutics, Stock Options, Director, Michael Dybbs, Form 4, Beneficial Ownership, Equity Securities, Vesting